PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Oct 2020
Historique:
received: 22 04 2020
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 3 7 2021
Statut: epublish

Résumé

Poly (ADP-ribose) polymerase 1 (PARP1), as a key enzyme in the base excision repair pathway, plays a crucial role in tumorigenesis and progression. This study aimed to assess whether polymorphisms of PARP1 gene could be used as predictive biomarkers for the survival of esophageal squamous cell carcinoma (ESCC) patients from Cixian high-incidence region in northern China. In 203 ESCC patients with survival information, PARP1 rs1136410 T/C and rs8679 T/C single nucleotide polymorphisms (SNPs) were genotyped by polymerase chain reaction ligase detection reaction (PCR-LDR) method. All statistical analyses were performed using the SPSS ver. 22.0 software package (SPSS, Chicago, IL, USA). The mean age ± standard deviation of the ESCC patients was 60.4 ± 7.9 years. There was no significant relation of sex, age, smoking status and upper gastrointestinal cancer family history with the survival time of the ESCC patients. The mean survival time of rs1136410 T/T, T/C and C/C genotype carriers were 43.3, 42.3 and 46.6 months, respectively. The rs1136410 was not associated with the survival time of the ESCC patients. For rs8679, the mean survival time of T/T genotype carriers was 43.7 months, which was not significantly different from that of the patients with T/C genotype (42.1 months). In Cixian high-incidence region from northern China, rs1136410 and rs8679 SNPs might not be used to predict survival of ESCC patients. There is a need to explore whether other SNPs of PARP1 gene have an effect on prognosis of ESCC patients.

Identifiants

pubmed: 33112558
doi: 10.31557/APJCP.2020.21.10.2987
pmc: PMC7798169
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2987-2992

Références

Dis Markers. 2016;2016:8289293
pubmed: 27746584
Cancer Sci. 2010 Nov;101(11):2436-42
pubmed: 20731661
Cancer Biol Ther. 2010 Jul 1;10(1):13-8
pubmed: 20495366
J Mol Med (Berl). 2000;78(8):431-40
pubmed: 11097112
Mol Cell Biochem. 2013 Jan;372(1-2):27-33
pubmed: 22983827
Oncol Lett. 2016 Nov;12(5):3825-3835
pubmed: 27895737
Mutagenesis. 2017 Oct 17;32(5):533-542
pubmed: 29048575
DNA Cell Biol. 2017 Aug;36(8):693-708
pubmed: 28598207
J Cancer. 2019 Jul 10;10(18):4159-4164
pubmed: 31413734
Cancer Sci. 2003 Jun;94(6):497-500
pubmed: 12824873
Breast Cancer Res Treat. 2011 May;127(1):273-81
pubmed: 21069454
Cancer Res. 2004 Jun 15;64(12):4378-84
pubmed: 15205355
Cancer Res. 2004 Sep 1;64(17):6344-8
pubmed: 15342424
Cancer Res. 2013 Jan 1;73(1):256-64
pubmed: 23108145
Carcinogenesis. 2002 Apr;23(4):599-603
pubmed: 11960912
Mol Diagn Ther. 2013 Aug;17(4):239-45
pubmed: 23633189
Eur J Cancer. 2006 Sep;42(14):2374-81
pubmed: 16809031
Biochem Biophys Res Commun. 2007 Mar 2;354(1):122-6
pubmed: 17214964
Cancer Med. 2018 Apr;7(4):1537-1545
pubmed: 29533003
Carcinogenesis. 2012 Mar;33(3):581-6
pubmed: 22166496
Nucleic Acids Res. 1988 Feb 11;16(3):1215
pubmed: 3344216
Genes Dev. 2005 Sep 1;19(17):1951-67
pubmed: 16140981
Nucleic Acids Res. 2003 Oct 1;31(19):5526-33
pubmed: 14500814
Br J Cancer. 2009 Jul 21;101(2):256-62
pubmed: 19568233
Jpn J Clin Oncol. 2005 Feb;35(2):97-102
pubmed: 15709096
PLoS One. 2012;7(7):e40131
pubmed: 22792228
Carcinogenesis. 2001 Jan;22(1):1-3
pubmed: 11159733
Biochemistry. 1998 Mar 17;37(11):3893-900
pubmed: 9521710
Nucleic Acids Res. 1996 Nov 15;24(22):4387-94
pubmed: 8948628
Tumour Biol. 2015 Mar;36(3):1539-48
pubmed: 25374063

Auteurs

Rong-Miao Zhou (RM)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Yan Li (Y)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Na Wang (N)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Chao-Xu Niu (CX)

Department of Surgery, Shijiazhuang Ping'an Hospital, Hebei Province, China.

Xi Huang (X)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Shi-Ru Cao (SR)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Xiang-Ran Huo (XR)

Hebei Provincial Cancer Institute, The Fourth Hospital of Hebei Medical University, Hebei Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH